COMP <GO>
RGEN vs TECH // DIVIDEND YIELD & FCF PAYOUT SAFETY
Repligen Corporation (NASDAQ) VS. Bio-Techne Corp (NASDAQ) • 15-METRIC TALLY: RGEN 3
— TECH 9
▲ DIVIDEND YIELD & FCF PAYOUT SAFETY LEADER: TECH
LAST: $176.94 (-6.20%) • MKT CAP: $10.69B
dividend-safety
0.00%
LAST: $72.66 (-0.07%) • MKT CAP: $11.40B
dividend-safety
0.44%
15-METRIC INSTITUTIONAL SIDE-BY-SIDE SCORECARD (RGEN VS. TECH)
EMERALD CELL = QUANTITATIVE EDGE
| INSTITUTIONAL METRIC | RGEN | TECH | SPREAD (A - B) | ADVANTAGE | DEDICATED URL |
|---|---|---|---|---|---|
| Gross Profit Margin | 88.20% | 64.80% | +23.40 | RGEN | /gross-margins <GO> |
| Return on Invested Capital (ROIC) | 2.30% | 3.40% | -1.10 | TECH | /roic <GO> |
| EV/EBITDA & P/E Valuation | 95.0x | 91.3x | +3.70 | TECH | /valuation <GO> |
| Free Cash Flow Yield | 0.88% | 2.25% | -1.37 | TECH | /fcf-yield <GO> |
| Operating Margin | 1.80% | 8.40% | -6.60 | TECH | /operating-margins <GO> |
| Net Profit Margin | 1.60% | 6.00% | -4.40 | TECH | /net-margins <GO> |
| Revenue Growth (YoY) | -3.30% | 5.20% | -8.50 | TECH | /revenue-growth <GO> |
| Dividend Yield & FCF Payout Safety ACTIVE | 0.00% | 0.44% | -0.44 | TECH | /dividend-safety <GO> |
| Altman Z-Score & Debt/Equity | 9.31 | 7.12 | +2.19 | RGEN | /balance-sheet <GO> |
| Piotroski F-Score Quality | 8/9 | 8/9 | 0.00 | TIE | /piotroski-score <GO> |
| Options Implied Move & Put/Call Skew | — | — | — | TIE | /options-implied-move <GO> |
| RSI-14 & 200D SMA Momentum | 56.7 | 59.3 | -2.60 | TECH | /rsi-technicals <GO> |
| 10Y Yield & FRED Macro Beta | 1.04 | 0.88 | +0.16 | RGEN | /macro-sensitivity <GO> |
| Forward P/E Multiple | — | 140.0x | — | TIE | /forward-pe <GO> |
| Enterprise Scale & Market Cap | $10.69B | $11.40B | -$707.7M | TECH | /market-cap <GO> |
5-YEAR HISTORICAL XBRL REVENUE & MARGIN TRAJECTORY SEC FORM 10-K FY
| FISCAL YEAR | RGEN REV | TECH REV | RGEN GROSS % | TECH GROSS % | RGEN FCF | TECH FCF |
|---|---|---|---|---|---|---|
| FY 2025 | $0 | $1.22B | — | 64.8% | $93.9M | $256.6M |
| FY 2024 | $0 | $1.16B | — | 66.4% | $149.7M | $236.1M |
| FY 2023 | $0 | $1.14B | — | — | $113.9M | $203.2M |
FRED MACRO REGIME CORRELATION COMPARISON PEARSON r
RGEN // BETA 1.04
TECH // BETA 0.88